
Graham Collins, MBBS, on New Agents, Prognostic Models in Hodgkin Lymphoma
The HemOnc Pulse
00:00
Is Bleamycin a Good Treatment for ABVD?
The bottom line is not really. Certainly the fertility will take longer to get some proper results. And myeloid malignancies, yeah, we're going to have to wait another few years but important topics to address. Overall, I still think it's a slightly disappointing study because when you look at the stage three, four, seven-year PFS, it's 75%. It's basically the same as pretty much every other study with ABVD over the last sort of 10 years. So whilst it's definitely beneficial for reducing toxicity in interim pet negative patients, I'm not sure it's really shifted the bar in improving efficacy. That's where BECOP or ABD Breton
Transcript
Play full episode